GlassScriptPhysician profile
Bassim Badro
NPI 1215941695
$14,164.81
in general payments reported to CMS, 2019-2025
29 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,068 · 2020: $2,377 · 2021: $639 · 2022: $2,406 · 2023: $3,032 · 2024: $1,442 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,355 · Travel and Lodging: $1,300 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,354.60 |
| Travel and Lodging | $1,300.46 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,493.60 | 2021-2025 | Selectsecure, Micra, Azure Xt Dr Mri Surescan |
| Medtronic Vascular, INC. | $2,425.11 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $1,867.71 | 2020-2024 | |
| Abbott Laboratories | $535.33 | 2019-2024 | Cardiomems, Tendril |
| Novartis Pharmaceuticals Corporation | $394.85 | 2019-2025 | |
| Boston Scientific Corporation | $247.81 | 2019-2025 | Watchman, Lux-Dx Insertable Cardiac Monitor |
| Pfizer INC. | $243.10 | 2019-2025 | |
| Inari Medical, INC. | $223.23 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kestra Medical Technology Services, INC. | $190.72 | 2022-2025 | Assure Wcd |
| Amgen INC. | $187.74 | 2019-2025 | Repatha, Repatha |
| Atricure, INC. | $186.46 | 2019-2024 | |
| Heartflow, INC. | $157.85 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $143.45 | 2022-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $141.68 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.51 | 2019-2024 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.11 | 2024-2025 | Lifevest |
| Preventice Services, LLC | $81.24 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $69.99 | 2019-2025 | Farxiga |
| Philips North America LLC | $68.35 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Amarin Pharma, INC. | $61.80 | 2019-2020 | |
| Biosense Webster, INC. | $44.19 | 2025 | Carto 3 |
| Novo Nordisk INC | $42.63 | 2024-2025 | Wegovy |
| Medicomp INC | $33.92 | 2020 | |
| Lantheus Medical Imaging, INC. | $20.69 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $18.96 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $18.81 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $18.35 | 2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassim Badro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.